William A. Carey, M.D.
Regenerative medicine has the potential to provide novel therapies for a number of diseases affecting newborns. William A. Carey, M.D., seeks to find innovative treatments for two such disorders for which there currently are no cures.
Abnormal growth and development of the lung, as seen in bronchopulmonary dysplasia and congenital diaphragmatic hernia, is a common cause of death and disability in the neonatal population. Likewise, an arrest in the development of the human brain, as seen in periventricular leukomalacia, may lead to long-term abnormalities in neurodevelopment, such as cerebral palsy and mental retardation.
Dr. Carey is pursuing antibody- and stem-cell-based therapies for these pulmonary and neurological conditions using histological, biochemical, imaging and physiological techniques.
Research in the fields of stem cell engineering and lung recellularization could lead to treatments for what otherwise would be lethal abnormalities of lung development.
Research in the field of neuroimmunology could provide safe and effective treatments for a variety of diseases affecting the central nervous system.
Significance to patient care
Bronchopulmonary dysplasia affects 10,000 babies annually in the U.S., leading to prolonged hospitalization, impaired developmental outcomes and even death.
More than 1,500 cases of congenital diaphragmatic hernia are seen each year in the U.S., with approximately 50 percent of these babies dying due to severe pulmonary hypoplasia.
Periventricular leukomalacia affects perhaps 25,000 babies in the U.S. each year, with lifelong impairments in movement, learning, behavior and self-care.
For each of the above conditions, there currently is no effective preventive strategy or curative treatment.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.